Obagi Medical Announces FDA Approval of Obagi saypha ChIQ Injectable Hyaluronic Acid Gel
Globe Newswire (Mon, 15-Jun 9:00 AM ET)
Waldencast Announces Sale of Obagi Medical to Bridgepoint
Globe Newswire (Mon, 1-Jun 6:59 AM ET)
Globe Newswire (Fri, 15-May 8:13 AM ET)
Obagi and Next Health Partner to Launch "The Skin Recharge Station" Pop-Up Experience
Globe Newswire (Thu, 14-May 8:15 AM ET)
Market Chameleon (Fri, 1-May 7:46 AM ET)
Market Chameleon (Thu, 30-Apr 7:10 AM ET)
Obagi Medical Unveils New Mineral Sunscreen Designed to Protect Sensitive and Post-Procedure Skin*
Globe Newswire (Thu, 30-Apr 8:14 AM ET)
Waldencast Announces SEC Investigation Conclusion: Favorable Outcome Signals Fresh Start
Market Chameleon (Wed, 29-Apr 5:54 AM ET)
Waldencast announces conclusion of SEC investigation
Globe Newswire (Tue, 28-Apr 6:12 PM ET)
Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.
Waldencast PLC - Class A Ordinary Share trades on the NASDAQ stock market under the symbol WALD.
As of July 27, 2026, WALD stock price climbed to $1.72 with 430,939 million shares trading.
WALD has a beta of 1.04, meaning it tends to be more sensitive to market movements. WALD has a correlation of 0.01 to the broad based SPY ETF.
WALD has a market cap of $218.90 million. This is considered a Small Cap stock.
Last quarter Waldencast PLC - Class A Ordinary Share reported $272 million in Revenue and -$2.01 earnings per share. This fell short of revenue expectation by $-14 million and missed earnings estimates by -$1.60.
In the last 3 years, WALD traded as high as $12.00 and as low as $.72.
WALD has underperformed the market in the last year with a return of -28.6%, while SPY returned +17.7%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in WALD shares. However, WALD has outperformed the market in the last 3 month and 2 week periods, returning +102.0% and -0.6%, while SPY returned +3.8% and -2.1%, respectively. This indicates WALD has been having a stronger performance recently.
WALD support price is $1.59 and resistance is $1.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that WALD shares will trade within this expected range on the day.
